Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Warfarin has been the established oral anticoagulant for the last 50 years, being effective in the prevention and treatment of venous and arterial thromboembolic disorders. However, the frequent requirement for INR monitoring, multiple drug and food interactions have fuelled the need for development of new oral anticoagulants. Dabigatran is the first of a series of new oral anticoagulants that are emerging as the successors to warfarin. This new group of anticoagulants is rapidly gaining FDA and NICE approval and has proven non-inferiority to warfarin and viable alternatives to warfarin in the coming years. Given the obvious impact of this on dental treatment in the primary care and hospital setting this article aims to increase familiarisation with this new medicine group.

Original publication

DOI

10.1038/sj.bdj.2013.628

Type

Journal article

Journal

Br Dent J

Publication Date

07/2013

Volume

215

Pages

17 - 20

Keywords

Anticoagulants, Antithrombin Proteins, Benzimidazoles, Dabigatran, Factor Xa Inhibitors, Humans, Morpholines, Prodrugs, Pyrazoles, Pyridines, Pyridones, Rivaroxaban, Thiophenes, Thromboembolism, Warfarin